This phase I trial studies the side effects and best dose of cabozantinib in treating younger patients with recurrent or refractory solid tumors. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
I. To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose of XL184 (cabozantinib) administered orally every day to children with refractory solid tumors including central nervous system (CNS) tumors.
II. To define and describe the toxicities of XL184 (cabozantinib) administered on this schedule.
III. To characterize the pharmacokinetics of XL184 (cabozantinib) in children with refractory solid tumors.
I. To preliminarily define the antitumor activity of XL184 (cabozantinib) within the confines of a Phase 1 study.
II. To assess the biologic activity of XL184 (cabozantinib). III. To assess the biomarker response (carcinoembryonic antigen [CEA] and calcitonin) in patients with medullary thyroid cancer treated with XL184.
OUTLINE: This is a dose-escalation study.
Patients receive cabozantinib orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically.